First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial). - Watabe T; Mukai K; Naka S; Sasaki H; Kamiya T; Hayakawa T; Fukuhara A; Takano T; Shirakami Y; Ooe K; Shigeno S; Okamura S; et al. (Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025)